The FDA has continued easing regulatory requirements for wearable health devices through 2026, extending a policy shift that began with the agency's decision to pull back oversight of many AI-enabled devices and wearables earlier in the year. Under the updated general wellness framework, a broader range of fitness and health-monitoring products can avoid the more rigorous device-clearance process as long as they stick to general wellness claims rather than diagnosing or treating specific conditions.
Manufacturers have largely welcomed the shift, arguing that lighter-touch rules let them ship new features faster in a market where consumer expectations are set by companies iterating on hardware every year. Critics counter that the line between a "wellness" claim and a genuine medical claim has grown blurrier as wearables add capabilities like continuous glucose estimation, sleep apnea flags and heart-rhythm analysis — features that look a lot like clinical tools even without formal device clearance.
The policy comes as competition intensifies among device makers to bundle more health-monitoring features into everyday wearables, and as the FDA separately works on generative AI guidance for higher-risk clinical software. Regulators say the two efforts are meant to be complementary: lighter oversight for low-risk wellness features, paired with clearer rules for AI systems making higher-stakes clinical judgments.
